These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15319859)

  • 1. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use.
    Freeman AJ; Ffrench RA; Post JJ; Harvey CE; Gilmour SJ; White PA; Marinos G; van Beek I; Rawlinson WD; Lloyd AR
    J Infect Dis; 2004 Sep; 190(6):1093-7. PubMed ID: 15319859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection.
    Thurairajah PH; Hegazy D; Chokshi S; Shaw S; Demaine A; Kaminski ER; Naoumov NV; Cramp ME
    J Infect Dis; 2008 Dec; 198(12):1749-55. PubMed ID: 18959498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.
    Post JJ; Pan Y; Freeman AJ; Harvey CE; White PA; Palladinetti P; Haber PS; Marinos G; Levy MH; Kaldor JM; Dolan KA; Ffrench RA; Lloyd AR; Rawlinson WD;
    J Infect Dis; 2004 May; 189(10):1846-55. PubMed ID: 15122521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
    Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
    J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clearance of hepatitis C virus after newly acquired infection in injection drug users.
    Jauncey M; Micallef JM; Gilmour S; Amin J; White PA; Rawlinson W; Kaldor JM; van Beek I; Dore GJ
    J Infect Dis; 2004 Oct; 190(7):1270-4. PubMed ID: 15346337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells.
    Resti M; Azzari C; Moriondo M; Betti L; Sforzi I; Novembre E; Vierucci A
    Clin Infect Dis; 2002 Aug; 35(3):236-9. PubMed ID: 12115087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection.
    Graham CS; Wells A; Edwards EM; Herren T; Tumilty S; Stuver SO; Samet JH; Nunes D; Horsburgh CR; Koziel MJ
    J Infect Dis; 2007 Mar; 195(6):847-56. PubMed ID: 17299715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of multiple hepatitis virus infections in autopsied materials of intravenous drug addicts.
    Schleicher S; Schieffer M; Jürgens S; Wehner HD; Flehmig B
    Ig Sanita Pubbl; 2005; 61(5):435-50. PubMed ID: 17214028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activation and differentiation of naïve CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells.
    Krishnadas DK; Li W; Kumar R; Tyrrell LJ; Agrawal B
    Cell Immunol; 2009; 259(2):141-9. PubMed ID: 19616202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance.
    Folgori A; Spada E; Pezzanera M; Ruggeri L; Mele A; Garbuglia AR; Perrone MP; Del Porto P; Piccolella E; Cortese R; Nicosia A; Vitelli A;
    Gut; 2006 Jul; 55(7):1012-9. PubMed ID: 16484505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virus.
    Ríos M; Diago M; Rivera P; Tuset C; Cors R; García V; Carbonel P; Gonzalez C
    J Viral Hepat; 2006 Mar; 13(3):177-81. PubMed ID: 16475993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of hepatitis C virus infection in the largest province of Pakistan.
    Idrees M; Lal A; Naseem M; Khalid M
    J Dig Dis; 2008 May; 9(2):95-103. PubMed ID: 18419643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus reinfection in injection drug users.
    Grebely J; Conway B; Raffa JD; Lai C; Krajden M; Tyndall MW
    Hepatology; 2006 Nov; 44(5):1139-45. PubMed ID: 17058216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee.
    Youn JW; Park SH; Lavillette D; Cosset FL; Yang SH; Lee CG; Jin HT; Kim CM; Shata MT; Lee DH; Pfahler W; Prince AM; Sung YC
    Hepatology; 2005 Dec; 42(6):1429-36. PubMed ID: 16317673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance.
    Ruys TA; Nanlohy NM; van den Berg CH; Hassink E; Beld M; van de Laar T; Bruisten S; Wit F; Krol A; Prins M; Lange J; van Baarle D
    J Viral Hepat; 2008 Jun; 15(6):409-20. PubMed ID: 18221302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological responses in patients who have spontaneously eradicated hepatitis C virus infection.
    Zitron IM; Laurinaitis M; Qu L; Silverman AL; Gordon SC
    Viral Immunol; 2000; 13(4):521-31. PubMed ID: 11192299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
    Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
    J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection.
    Morishima C; Shuhart MC; Yoshihara CS; Paschal DM; Silva MA; Thomassen LV; Emerson SS; Gretch DR
    J Infect Dis; 2007 Aug; 196(4):577-86. PubMed ID: 17624844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HIV on host-virus interactions during early hepatitis C virus infection.
    Danta M; Semmo N; Fabris P; Brown D; Pybus OG; Sabin CA; Bhagani S; Emery VC; Dusheiko GM; Klenerman P
    J Infect Dis; 2008 Jun; 197(11):1558-66. PubMed ID: 18419344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.
    Micallef JM; Macdonald V; Jauncey M; Amin J; Rawlinson W; van Beek I; Kaldor JM; White PA; Dore GJ
    J Viral Hepat; 2007 Jun; 14(6):413-8. PubMed ID: 17501762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.